Dr Reddy’s labs announced on Tuesday it had launched tablets of Famotidine, an over-the-counter (OTC) drug, used to treat gastroesophageal reflux disease on the US market.
The company launched the product, which is equivalent to Johnson & Johnson’s Pepcid AC, in the United States after obtaining approval from the United States Food and Drug Administration (USFDA), Dr. Reddy’s labs said in a report. communicated.
Famotidine tablets are used to prevent and relieve heartburn associated with acid indigestion and heartburn caused by eating or consuming certain foods and beverages.
This launch will help us fill a significant therapeutic gap created in the antacid market due to the withdrawal of ranitidine, ”said Marc Kikuchi, CEO of Dr Reddy’s Laboratories North America Generics.
The Pepcid AC brand and generic versions achieved US sales of approximately US $ 211 million for the 12 months ended August 2020.
(Only the title and image of this report may have been reworked by Business Standard staff; the rest of the content is automatically generated from a syndicated feed.)
Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting-edge commentary on relevant current issues. However, we have a demand.
As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.